CareDx Executive Compensation (FY25)
CDNA · Executive and director compensation, fiscal 2025 only
The CareDx brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 16, 2026Latest filing (8-K): June 15, 2026
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
195 figures on this page: 188 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is CareDx's chief executive and what were they paid?
John Hanna was paid $7,179,699 in total compensation as President and Chief Executive Officer for fiscal 2025.
What was CareDx's say-on-pay result?
The say-on-pay proposal drew 95.3% of votes cast including abstentions in favor at the meeting held June 11, 2026 for fiscal 2025.
Which companies are in CareDx's peer group?
The disclosed peer group names Adaptive Biotechnologies Corp., Castle Biosciences, Inc., Fulgent Genetics, Inc., Guardant Health, Inc. and Myriad Genetics, Inc., among others.
What is CareDx's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 48:1, against median employee compensation of $148,417.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Hanna President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Keith Kennedy Chief Operating Officer and Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Abhishek Jain Former Chief Financial Officer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jessica Meng Chief Commercial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jeffrey Novack General Counsel and Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Nathan Smith Former Chief Financial Officer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Abhishek Jain | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jeffrey Novack | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jessica Meng | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John W. Hanna | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Keith Kennedy | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Nathan Smith | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Jeffrey Novack | Option | ◇ | — | ◇ | 4/6/2032 |
| Option | ◇ | — | ◇ | 8/6/2032 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Abhishek Jain | Option | ◇ | — | ◇ | 4/18/2032 |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/1/2033 | |
| Option | ◇ | — | ◇ | 9/7/2032 | |
| Option | ◇ | — | ◇ | 5/26/2032 | |
| Keith Kennedy | Option | ◇ | — | ◇ | 9/12/2034 |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Jessica Meng | Option | ◇ | — | ◇ | 9/12/2034 |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| John Hanna | Option | ◇ | — | ◇ | 4/15/2034 |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Nathan Smith | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Abhishek Jain
Former Chief Financial Officer · Change-in-control agreement · citing a 2026 filing
| Severance base | ◇ |
Jeffrey Novack
General Counsel and Secretary · Change-in-control agreement · citing a 2026 filing
| Severance base | ◇ |
Jessica Meng
Chief Commercial Officer · Change-in-control agreement · citing a 2026 filing
| Severance base | ◇ |
John Hanna
President and Chief Executive Officer · Change-in-control agreement · citing a 2026 filing
| Severance base | ◇ |
Keith Kennedy
Chief Operating Officer and Chief Financial Officer · Change-in-control agreement · citing a 2026 filing
| Severance base | ◇ |
Nathan Smith
Former Chief Financial Officer · Change-in-control agreement · citing a 2026 filing
| Severance base | ◇ |
| Equity acceleration on change in control | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Suresh Gunasekaran | ◇ | ◇ | — | — | — | — | ◇ |
Michael D. Goldberg Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Christine M. Cournoyer | ◇ | ◇ | — | — | — | — | ◇ |
George W. Bickerstaff, III | ◇ | ◇ | — | — | — | — | ◇ |
R. Bryan Riggsbee | ◇ | ◇ | — | — | — | — | ◇ |
Hannah A. Valantine, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Arthur A. Torres | ◇ | ◇ | — | — | — | — | ◇ |
Fred E. Cohen, M.D., D. Phil | ◇ | ◇ | — | — | — | — | ◇ |
Peter Maag, Ph.D | ◇ | ◇ | — | — | — | — | ◇ |
William A. Hagstrom | ◇ | — | — | — | — | — | ◇ |
John W. Hanna served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Stock ownership guideline: 3x annual cash retainer
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Adaptive Biotechnologies Corp. ADPT
- Castle Biosciences, Inc. CSTL
- Fulgent Genetics, Inc. FLGT
- Guardant Health, Inc. GH
- Myriad Genetics, Inc. MYGN
- Natera, Inc. NTRA
- NeoGenomics, Inc. NEO
- Pacific Biosciences of California, PACB
- Quanterix Corporation QTRX
- TransMedics Group TMDX
- Twist Bioscience Corporation TWST
- Veracyte, Inc. VCYT
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 11, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 12, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 13, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 15, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 15, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 15, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 17, 2020 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact CareDx disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where CareDx sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
195 figures on this page: 188 cited to the filing that reported them, 7 calculated from figures it prints.
188 cited to the filing
7 calculated from the filing
Documents cited
- 0001217234-26-000036Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers.
- 0001217234-26-000028Director Compensation · Director Compensation Table · EBITDA · Outstanding Equity Awards at Fiscal Year-End · and 2 more sections
- 0001193125-25-139978Proposal No. 3 - To approve, on an advisory basis, the compensation of the Company’s named executive officers.
- 0001217234-24-000071
- 0001217234-23-000107
- 0001217234-22-000109
- 0001193125-21-193438Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001217234-20-000106Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001217234-26-000018
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “CareDx executive compensation, FY2025.” https://intel.velarion.ai/comp/CDNA (accessed 2026).
Short form: data: Velarion
The CareDx brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about CareDx and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers CareDx discloses
The companies named in CDNA's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}